<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recurrent adverse pregnancy outcome may be the final result of different causes, including <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, as the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid Syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> (<z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and/or anticardiolipin antibodies) were found in 16% of 197 patients with prior unexplained <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent miscarriages</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>During our study 22 out of 32 <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> positive women became pregnant again </plain></SENT>
<SENT sid="3" pm="."><plain>To prevent abortion relapses, 16 of them were treated with <z:chebi fb="0" ids="15365">acetylsalicylic acid</z:chebi> (50 mg x 2/day) and/or fluocortolone (20 mg/day for 5 days/week) </plain></SENT>
<SENT sid="4" pm="."><plain>Such therapy started as soon as pregnancy was diagnosed in 14 patients </plain></SENT>
<SENT sid="5" pm="."><plain>Two patients began the therapeutic regimen during the third month of gestation </plain></SENT>
<SENT sid="6" pm="."><plain>Six patients, who didn't accept this therapeutic approach, represent our control group </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the 14 early treated patients ended pregnancy with success </plain></SENT>
<SENT sid="8" pm="."><plain>The 2 women that began the therapy later presented abortion relapses </plain></SENT>
<SENT sid="9" pm="."><plain>Among the 6 not treated patients, 5 presented <z:hpo ids='HP_0005268'>spontaneous abortion</z:hpo> and only one gave birth to a baby </plain></SENT>
<SENT sid="10" pm="."><plain>No side effect was observed neither in treated mothers nor in their babies </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, even if further studies would be necessary to standardise a therapeutic protocol, our results encourage the clinical care of patients with <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and adverse pregnancy outcomes </plain></SENT>
</text></document>